Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07372768

Lifting the Impacted Fetal Head; the Fetal Pillow and Tydeman Tube Trial

A single centre prospective observational comparison trial to compare the Tydeman Tube and Fetal Pillow, to aid delivery of the impacted fetal head at full dilatation caesarean section, and to evaluate the use of the Tydeman Tube at 7-9cm.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

16 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

About this study

An impacted fetal head is a common complication encountered in 11% of all emergency caesarean sections and 65% of those performed at full dilatation. A recent UK Obstetric Surveillance Survey (UKOSS) highlighted significant maternal and neonatal complications secondary to an impacted fetal head, with 3% of babies dying or suffering a severe injury, and 6.1% of mother's requiring admission to intensive care, emphasizing the need to evaluate techniques and new devices to aid delivery. NHS resolution's early notification scheme implicated an impacted fetal head as a contributing factor in 9% of all severe neonatal brain injuries in 2019. There is no consensus amongst clinicians on the best management of an impacted fetal head, and with exponentially rising rates of intrapartum caesarean sections, improved management tools are urgently required.

This study will compare maternal and neonatal outcomes using two devices to aid delivery of an impacted fetal head at full dilatation caesarean section (FDCS)- the Tydeman Tube, a new UK Conformity Assessed (UKCA) and European Conformity (CE) marked device, and the Fetal Pillow, an existing CE marked device used commonly in clinical practice. There will be a separate observational sub study evaluating the use of the Tydeman Tube for managing an impacted fetal head at 7-9cm dilated. The study will also explore the acceptability of both devices to women and clinicians using postnatal questionnaires.

Participants will be all women requiring a full dilatation caesarean section who meet eligibility criteria. The study will be run in two consecutive arms - firstly, obstetricians and midwives will be trained to use the Fetal Pillow. The Fetal Pillow will then be introduced into clinical practice for 3-6 months. Following this the Fetal Pillow will be removed from clinical practice. Midwives and Obstetricians will then be trained to use the Tydeman Tube, which will be introduced into clinical practice for a further 3-6 months. During the Tydeman Tube arm of the trial, women undergoing caesarean section at 7-9cm who are found to have an impacted fetal head unexpectedly at the time of caesarean section are eligible for the observational sub study. If the operating surgeon believes the Tydeman Tube is required for the clinical situation then it may be used.

The trial is a prospective observational comparison trial with an additional observational sub study. The results of this study will be used to improve understanding on the best management techniques for an impacted fetal head.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Undergoing caesarean section at full dilataion for fetal pillow arm, or caesarean section at 7 or more centimetres dilated for the tydeman tube arm
  • Singleton pregnancy
  • Cephalic presentation

Exclusion criteria

  • Allergy to silicone rubber
  • Major congenital abnormalities
  • Major anomaly of the fetal head (i.e. large encephalocele)
  • Intrauterine death
  • Suspected chorioamnionitis
  • Active genital infection inc. Herpes Simplex Virus
  • Cervical dilatation <10cm for fetal pillow arm and <7cm for tydeman tube arm
  • Gestational age <37 weeks
  • non-cephalic presentation

Treatment and study plan

Fetal Pillow

Device

The Fetal Pillow is a CE marked single use sterile device. It is used in Caesarean sections performed at full dilatation. The Fetal Pillow is designed to atraumatically elevate the fetal head out of the pelvis before a caesarean section begins, making the delivery safer, easier and less traumatic. It comprises of a base plate, which is placed posteriorly in the vagina between the fetal head and the vaginal wall. It is then slowly inflated with 180mls of water via a thin tube, which aims to elevate the fetal head. It is removed at the end of the caesarean section.

Some evidence for the Fetal Pillow suggests it can reduce maternal and fetal complications from FDCS by enabling elevation of a deeply engaged head, with some studies demonstrating a reduction in uterine incision extensions, lower estimated blood lossand fewer neonatal intensinve care (NICU)admissions. However evidence is conflicting and newer randomised control trials suggest no difference in outcome when using the device.

Tydeman Tube

Device

The Tydeman Tube is a UKCA/CE marked single use sterile device designed to aid delivery of an impacted fetal head at caesarean section. It consists of a semi-rigid wide bore silicone tube and flexible silicone cup.The tube is inserted into the vagina before or during caesarean section where an impacted fetal head is anticipated or encountered. It can be used from 7-10cm dilated. The cup fits against the baby's head. The tube is held by the assistant and used to elevate the head by pushing upwards. This disimpacts the head from the pelvis and brings it towards the surgeon's hand to enable delivery. The cup dissipates the force applied evenly over a wide area of the head which is intended to prevent fetal trauma. Once the surgeon has gained access below the head, the wide bore tube and design of the cup allows air to enter below the head during delivery to limit suction effect. Once the baby is delivered the Tydeman Tube is removed from the vagina.

Primary outcomes

  1. Time from uterine incision to delivery

    Time frame: 4 weeks

    Seconds

Secondary outcomes

  1. Uterine incision to closure time

    Time frame: 4 weeks

    Seconds

  2. Estimated blood loss

    Time frame: 4 weeks

    mLs

  3. Requirement of blood products

    Time frame: 4 weeks

    Yes/No

  4. Volume of blood products

    Time frame: 4 weeks

    Dependent on type of product

  5. Presence of uterine angle extensions

    Time frame: 4 weeks

    Yes/No

  6. Presence of visceral injury

    Time frame: 4 weeks

    Yes/No - visceral injuries may include ureter, cervix, bladder, bowel

  7. Need for hysterectomy

    Time frame: 4 weeks

    Yes/No

  8. Presence of genital tract trauma

    Time frame: 4 weeks

    Yes/No - genital tract trauma may include lacerations and haematomas

  9. Admission to HDU/ITU

    Time frame: 4 weeks

    Yes/No

  10. Maternal death

    Time frame: 4 weeks

    Yes/No

  11. Length of stay

    Time frame: 4 weeks

    Days

  12. Wound infection

    Time frame: 4 weeks

    Yes/No

  13. Endometritis

    Time frame: 4 weeks

    Yes/No

  14. Change in maternal haemoglobin (Hb)

    Time frame: 4 weeks

    Difference in measured Hb before caesarean and after caesarean

  15. Presence of birth trauma to the neonate

    Time frame: 4 weeks

    Yes/No - birth trauma may include intracranial haemorrhage, skull fracture, other fracture, facial nerve injury (bruising/facial nerve palsy/other nerve injury)

  16. Apgar score

    Time frame: 4 weeks

    Routine test taken of the newborn infant based on Appearance (colour), Pulse (heart rate), Grimace (reflexes), Activity (muscle tone) and Respiration (breathing) at 5 and 10 minutes - scored from 0-10 with lower scores indicating poor condition and need for assessment/intervention

  17. Resuscitation required

    Time frame: 4 weeks

    Yes/No

  18. Admission to special care baby unit (SCBU) or neonatal intensive care unit (NICU)

    Time frame: 4 weeks

    Yes/No

  19. Length of stay in higher care

    Time frame: 4 weeks

    Days

  20. Arterial cord pH measurement

    Time frame: 4 weeks

    Measures the acidity of a newborn's blood from the umbilical artery, reflecting fetal oxygenation and metabolic state at birth, with normal ranges around 7.18-7.38, lower values (<7.0) can signal distress, risk of neurological issues and often require neonatal observation

  21. Diagnosis of hypoxic-ischaemic encephalopathy (HIE)

    Time frame: 4 weeks

    Yes/No and Grading (1,2,3)

    HIE is a brain injury from lack of oxygen and/or blood flow to the brain around the time of birth, affecting newborns. It is associated with potential long-term disability including cerebral palsy or developmental delay, and in severe cases death. Symptoms include seizures, poor feeding and altered alternates. It is graded as mild (Grade 1), moderate (Grade 2) and severe (Grade 3)

  22. Perinatal death

    Time frame: 4 weeks

    Yes/No

  23. Neonatal feeding

    Time frame: 4 weeks

  24. Evaluation of Fetal Pillow / Tydeman tube using Lickert scale questionnaires (clinician)

    Time frame: 4 weeks

    Acceptability, ease of use, perception of impacted head and perception of ease of delivery will be assessed using Lickert scale questionnaires where participants will be asked to rate their level of agreement or feeling on a symmetrical scale, form one extreme to another (i.e. 'strongly disagree' to 'strongly agree')

  25. Acceptability of Fetal Pillow / Tydeman Tube using Lickert scan questionnaires (maternal)

    Time frame: 4 weeks

    Patients perception of the acceptability of the two devices will be assessed using Lickert scale questionnaires where participants will be asked to rate their level of agreement or feeling on a symmetrical scale, form one extreme to another (i.e. 'strongly disagree' to 'strongly agree')

Study contacts

Contact information is provided by the study sponsor or research team.

Andrew Shennan, MD

CONTACT

[email protected]

Laura van der Krogt, MBBS

CONTACT

[email protected]

+4420 7836 5454.

Sponsors and collaborators

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust

Other

Collaborators

  • King's College London

Registry information

Acronym: LIFT

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 28, 2026
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.